One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Flashback Foreword: Chimeric Anti-CD20 Monoclonal Antibody Therapy.
Friedberg, Jonathan W. MD, MMSc 1,2,3,,
doi : 10.1200/JCO.22.02425
Volume 41(2) pgs. 151-422 January 10, 2023
JCO Flashback: Evaluating Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed B-cell Lymphoma (1998).
doi : 10.1200/JCO.22.02738
Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program.
McLaughlin, P; Grillo-Lopez, A J; Link, B K; Levy, R; Czuczman, M S; Williams, M E; Heyman, M R; Bence-Bruckler, I; White, C A; Cabanillas, F; Jain, V; Ho, A D; Lister, J; Wey, K; Shen, D; Dallaire, B K
doi : 10.1200/JCO.22.02403
The CD20 antigen is expressed on more than 90% of B-cell lymphomas. It is appealing for targeted therapy, because it does not shed or modulate. A chimeric monoclonal antibody more effectively mediates host effector functions and is itself less immunogenic than are murine antibodies.
Risk Stratification of Nonmuscle Invasive Bladder Cancer and Innovative Approaches to Management of Ta Low-Grade Tumors.
Kim, Sung Han MD, PhD 1,2; Lerner, Seth P. MD 2,,
doi : 10.1200/JCO.22.02104
Melanoma: Does Sequencing Really Matter?.
Chandra, Sunandana MD, MS 1,,; Choi, Jacob S. MD, PhD 1; Sosman, Jeffrey A. MD 1,
doi : 10.1200/JCO.22.01354
Cost Savings and Increased Access With Ultra-Low-Dose Immunotherapy.
Mitchell, Aaron P. MD, MPH 1,,; Goldstein, Daniel A. MD 2,3,4,5,
doi : 10.1200/JCO.22.01711
Achieving a Cure Without Total Mesorectal Excision in Rectal Adenocarcinoma.
Hall, William A. MD 1,; Smith, J. Joshua MD, PhD 2,,
doi : 10.1200/JCO.22.01812
AB The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches.
Decentralized Clinical Trials in Oncology: Are We Ready for a Virtual-First Paradigm?.
Fu, Sherry BS 1,; Gerber, David E. MD 1,2,; Beg, Muhammad Shaalan MD, MS 1,2,3,,
doi : 10.1200/JCO.22.00358
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.
Atkins, Michael B. MD 1,,; Lee, Sandra J. ScD 2,; Chmielowski, Bartosz MD 3,; Tarhini, Ahmad A. MD, PhD 4,; Cohen, Gary I. MD 5,; Truong, Thach-Giao MD 6,; Moon, Helen H. MD 7,; Davar, Diwakar MD 8,; O'Rourke, Mark MD 9; Stephenson, Joseph J. MD 9; Curti, Brendan D. MD 10,; Urba, Walter J. MD, PhD 10,; Brell, Joanna M. MD 11; Funchain, Pauline MD 12,; Kendra, Kari L. MD, PhD 13,; Ikeguchi, Alexandra P. MD 14; Jaslowski, Anthony MD 15; Bane, Charles L. MD 16; Taylor, Mark A. MD 17; Bajaj, Madhuri MD 18; Conry, Robert M. MD 19; Ellis, Robert J. MD 20; Logan, Theodore F. MD 21,; Laudi, Noel MD 22,; Sosman, Jeffrey A. MD 23,; Crockett, David G. MD 24; Pecora, Andrew L. MD 25,; Okazaki, Ian J. MD 26; Reganti, Sowjanya MD 27; Chandra, Sunandana MD, MS 23,; Guild, Samantha JD 28; Chen, Helen X. MD 29; Streicher, Howard Z. MD 29; Wolchok, Jedd D. MD, PhD 30,; Ribas, Antoni MD, PhD 3,; Kirkwood, John M. MD 8
doi : 10.1200/JCO.22.01763
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial.
Rugo, Hope S. MD 1,,; Im, Seock-Ah MD, PhD 2,; Cardoso, Fatima MD 3,; Cortes, Javier MD, PhD 4,5,; Curigliano, Giuseppe MD, PhD 6,; Musolino, Antonino MD, PhD, MSc 7,8,9,; Pegram, Mark D. MD 10,; Bachelot, Thomas MD, PhD 11,; Wright, Gail S. MD, FACP, FCCP 12,; Saura, Cristina MD, PhD 13,; Escriva-de-Romani, Santiago MD 13,; De Laurentiis, Michelino MD, PhD 14,; Schwartz, Gary N. MD 15; Pluard, Timothy J. MD 16,; Ricci, Francesco MD 17; Gwin, William R. III MD 18,; Levy, Christelle MD 19; Brown-Glaberman, Ursa MD 20,; Ferrero, Jean-Marc MD 21,; de Boer, Maaike MD, PhD 22,; Kim, Sung-Bae MD, PhD 23,; Petrakova, Katarina MD, PhD 24,; Yardley, Denise A. MD 25,; Freedman, Orit MD, FRCP(C), MSc 26; Jakobsen, Erik H. MD 27,; Gal-Yam, Einav Nili MD, PhD 28,; Yerushalmi, Rinat MD 29,; Fasching, Peter A. MD 30,; Kaufman, Peter A. MD 31,; Ashley, Emily J. BS 32,; Perez-Olle, Raul MD, PhD 32,33,; Hong, Shengyan PhD 32,; Rosales, Minori Koshiji MD, PhD 32,33,; Gradishar, William J. MD 34,; on behalf of the SOPHIA Study Group
doi : 10.1200/JCO.21.02937
AB Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available.
DaBlaCa-13 Study: Oncological Outcome of Short-Term, Intensive Chemoresection With Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial.
Lindgren, Maria S. MD 1,2,3,,; Hansen, Erik MD 2,3; Azawi, Nessn MD, PhD 4; Nielsen, Anna M. BSN 1,; Dyrskjot, Lars PhD 3,5,; Jensen, Jorgen B. DMSc, MD 1,2,3,
doi : 10.1200/JCO.22.00470
This study aimed to assess long-term follow-up after chemoresection with mitomycin (MMC), a nonsurgical treatment modality for recurrent nonmuscle invasive bladder cancer (NMIBC).
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial.
Ascierto, Paolo A. MD 1,,; Mandala, Mario MD 2,3,; Ferrucci, Pier Francesso MD 4,; Guidoboni, Massimo MD 5,; Rutkowski, Piotr MD, PhD 6,; Ferraresi, Virginia MD 7,; Arance, Ana MD 8,; Guida, Michele MD 9; Maiello, Evaristo MD 10; Gogas, Helen MD, PhD 11,; Richtig, Erika MD 12,; Fierro, Maria Teresa MD 13; Lebbe, Celeste MD, PhD 14,; Helgadottir, Hildur MD, PhD 5; Queirolo, Paola MD 15,16,; Spagnolo, Francesco MD, PhD 15,; Tucci, Marco MD, PhD 17,; Del Vecchio, Michele MD 18,; Gonzales Cao, Maria MD, PhD 19,; Minisini, Alessandro Marco MD, PhD 20,; De Placido, Sabino MD 21,; Sanmamed, Miguel F. MD, PhD 22,; Mallardo, Domenico PhD 1; Curvietto, Marcello BS 1; Melero, Ignacio MD, PhD 22,; Palmieri, Giuseppe MD 23,; Grimaldi, Antonio M. MD 1,24,; Giannarelli, Diana MS 25,; Dummer, Reinhard MD 26,; Chiarion Sileni, Vanna MD 27,
doi : 10.1200/JCO.21.02961
Limited prospective data are available on sequential immunotherapy and BRAF/MEK inhibition for BRAFV600-mutant metastatic melanoma. METHODS: SECOMBIT is a randomized, three-arm, noncomparative phase II trial (ClinicalTrials.gov identifier: NCT02631447).
Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study.
Patil, Vijay Maruti MBBS, MD, DM 1,; Noronha, Vanita MBBS, MD, DM 1,; Menon, Nandini MBBS, MD, DNB 1; Rai, Rahul MBBS, MD 1; Bhattacharjee, Atanu PhD 2; Singh, Ajay MBBS, MD, DM 1; Nawale, Kavita PDCR 1; Jogdhankar, Shweta MSc 1; Tambe, Rupali BCom 1; Dhumal, Sachin BHMS 1; Sawant, Riddhi PDCR 1; Alone, Mitali MSc 1; Karla, Devanshi MSc 1; Peelay, Zoya MSc 1; Pathak, Shruti MSc 1; Balaji, Arun MASLP 3; Kumar, Suman MBBS, DNB 4; Purandare, Nilendu MBBS, DNB 5; Agarwal, Archi MBBS, DNB 5; Puranik, Ameya MBBS, DNB 5; Mahajan, Abhishek MBBS, DNB 4; Janu, Amit MBBS, DNB 4; Kumar Singh, Gunjesh MBBS, MD, DM 1; Mittal, Neha MBBS, MD 6; Yadav, Subhash MBBS, MD 6; Banavali, Shripad MBBS, MD 1; Prabhash, Kumar MBBS, MD, DM 1,,
doi : 10.1200/JCO.22.01015
The regimens approved for the treatment of advanced head and neck squamous cell carcinoma are accessible to only 1%-3% of patients in low- and middle-income countries because of their cost. In our previous study, metronomic chemotherapy improved survival in this setting
Neoadjuvant Chemotherapy, Excision, and Observation for Early Rectal Cancer: The Phase II NEO Trial (CCTG CO.28) Primary End Point Results.
Kennecke, Hagen F. MD, MHA 1,,; O'Callaghan, Chris J. PhD, DVM, MSc 2; Loree, Jonathan M. MD, MS 3,; Moloo, Hussein MD, MPH 4,; Auer, Rebecca MD, MSc 4,; Jonker, Derek J. MD 4; Raval, Manoj MD, MSc 5,; Musselman, Reilly MD 4; Ma, Grace MD 6; Caycedo-Marulanda, Antonio MD 6,; Simianu, Vlad V. MD 7,; Patel, Sunil MD 2; Pitre, Lacey D. MD 8,; Helewa, Ramzi MD, MSc 9; Gordon, Vallerie L. MD 10,; Neumann, Katerina MSc, PhD, MD 11; Nimeiri, Halla MD 12,; Sherry, Max MSc, MBA 2; Tu, Dongsheng PhD 2; Brown, Carl J. MD, MSc 5,
doi : 10.1200/JCO.22.00184
Organ-sparing therapy for early-stage I/IIA rectal cancer is intended to avoid functional disturbances or a permanent ostomy associated with total mesorectal excision (TME).
Physical Activity in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance).
Brown, Justin C. PhD 1,2,3,; Ma, Chao MS 4; Shi, Qian PhD 5,; Fuchs, Charles S. MD, MPH 6,; Meyer, Jeffrey BS 4,; Niedzwiecki, Donna PhD 7; Zemla, Tyler MS 5; Couture, Felix MD 8,; Kuebler, Philip MD 9; Kumar, Pankaj MD 10; Lewis, DeQuincy MD 11,; Tan, Benjamin MD 12,; Krishnamurthi, Smitha MD 13,; O'Reilly, Eileen M. MD 14,; Shields, Anthony F. MD 15,; Meyerhardt, Jeffrey A. MD, MPH 4,
doi : 10.1200/JCO.22.00171
To determine the specific types, durations, and intensities of recreational physical activity associated with the greatest improvements in disease-free survival (DFS) of patients with colon cancer.
Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study.
Andre, Thierry MD 1,,; Tougeron, David MD, PhD 2,; Piessen, Guillaume MD, PhD 3,; de la Fouchardiere, Christelle MD 4,; Louvet, Christophe MD, PhD 5,; Adenis, Antoine MD, PhD 6,; Jary, Marine MD 7,; Tournigand, Christophe MD, PhD 8,; Aparicio, Thomas MD, PhD 9,; Desrame, Jerome MD 10,; Lievre, Astrid MD, PhD 11,; Garcia-Larnicol, Marie-Line MD 12; Pudlarz, Thomas MD 1; Cohen, Romain MD, PhD 1,; Memmi, Salome MD, PhD 13; Vernerey, Dewi PhD 14,15,; Henriques, Julie MSc 14,15; Lefevre, Jeremie H. MD, PhD 16,; Svrcek, Magali MD, PhD 13,
doi : 10.1200/JCO.22.00686
In patients with resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma, surgery plus perioperative platinum-based chemotherapy is the standard of care.
Perioperative Beta-Blocker Supply and Survival in Women With Epithelial Ovarian Cancer and a History of Cardiovascular Conditions.
Spilsbury, Katrina PhD 1,2,; Tuesley, Karen M. MEpi 2,3; Pearson, Sallie-Anne PhD 4; Coory, Michael D. PhD 5; Donovan, Peter MBBS 6,7; Steer, Christopher B. MBBS 8,9,; Stewart, Louise M. PhD 10; Pandeya, Nirmala PhD 2,3; Jordan, Susan J. PhD 2,3,
doi : 10.1200/JCO.22.00097
Surgery for epithelial ovarian cancer (EOC) may activate stress-inflammatory responses that stimulate tumor growth and increase metastatic growth. Animal and in vitro studies have shown that inhibition of the catecholamine-induced inflammatory response via beta-adrenergic receptor blockade has antitumor potential in EOC.
A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor-Positive Ovarian Cancer (Study 006).
Tanyi, Janos L. MD, PhD 1,; Randall, Leslie M. MD, MS 2; Chambers, Setsuko K. MD 3; Butler, Kristina A. MD, MS 4; Winer, Ira S. MD, PhD 5; Langstraat, Carrie L. MD 6; Han, Ernest S. MD, PhD 7; Vahrmeijer, Alexander L. MD, PhD 8; Chon, Hye Sook MD 9; Morgan, Mark A. MD 10; Powell, Matthew A. MD 11; Tseng, Jill H. MD 12; Lopez, Alexis S. MD 9; Wenham, Robert M. MD, MS 9
doi : 10.1200/JCO.22.00291
The adjunctive use of intraoperative molecular imaging (IMI) is gaining acceptance as a potential means to improve outcomes for surgical resection of targetable tumors.
Symptoms and Needs Monitoring in Diverse Ambulatory Oncology Patients: Usage Characteristics and Impact on Emergency Room Visits and Hospitalization.
Natori, Akina MD, MSPH 1; Sookdeo, Vandana Devika MD, EMBA 2; Koru-Sengul, Tulay PhD 3; Schlumbrecht, Matthew MD, MPH 4,; Calfa, Carmen L. MD 1; Maclntyre, Jessica APRN, NP-C, AOCNP 5,; Benzo, Roberto M. PhD 2; Moreno, Patricia I. PhD 3; Crane, Tracy E. PhD, RDN 1,5; Garcia, Sofia F. PhD 6; Penedo, Frank J. PhD 1,5,7,,
doi : 10.1200/JCO.22.01038
Symptoms and needs monitoring using patient-reported outcomes (PRO) is associated with improved clinical outcomes in cancer care. However, these improvements have been observed predominantly in non-Hispanic White patients using English assessments with high completion rates.
Elevated C-Reactive Protein and Subsequent Patient-Reported Cognitive Problems in Older Breast Cancer Survivors: The Thinking and Living With Cancer Study.
Carroll, Judith E. PhD 1,2,; Nakamura, Zev M. MD 3; Small, Brent J. PhD 4; Zhou, Xingtao MS 5,6; Cohen, Harvey J. MD 7; Ahles, Tim A. PhD 8; Ahn, Jaeil PhD 5,6; Bethea, Traci N. PhD 6; Extermann, Martine MD 9,; Graham, Deena MD 10,; Isaacs, Claudine MD 6,; Jim, Heather S.L. PhD 11,; Jacobsen, Paul B. PhD 12; McDonald, Brenna C. PsyD 13; Patel, Sunita K. PhD 14; Rentscher, Kelly PhD 1,2; Root, James PhD 8; Saykin, Andrew J. PsyD 13,; Tometich, Danielle B. PhD 11; Van Dyk, Kathleen PhD 2; Zhai, Wanting MS 5,6; Breen, Elizabeth C. PhD 1,2; Mandelblatt, Jeanne S. MD 6
doi : 10.1200/JCO.22.00406
To examine longitudinal relationships between levels of C-reactive protein (CRP) and cognition in older breast cancer survivors and noncancer controls.
Inflammation and Clinical Decline After Adjuvant Chemotherapy in Older Adults With Breast Cancer: Results From the Hurria Older Patients Prospective Study.
Ji, Jingran MD 1; Sun, Can-Lan PhD 1,; Cohen, Harvey J. MD 2; Synold, Timothy PharmD 1,; Muss, Hyman MD 3; Sedrak, Mina S. MD, MS 1,,
doi : 10.1200/JCO.22.01217
Older breast cancer survivors are at increased risk of clinical decline after adjuvant chemotherapy. This study aimed to evaluate whether inflammatory markers assessed before adjuvant chemotherapy are associated with chemotherapy-induced clinical decline in a population of fit older adults with breast cancer.
Low-Intensity Adjuvant Chemotherapy for Breast Cancer in Older Women: Results From the Prospective Multicenter HOPE Trial.
Sedrak, Mina S. MD, MS 1,2,,; Sun, Can-Lan PhD 1,3,; Ji, Jingran MD 2; Cohen, Harvey J. MD 4; Gross, Cary P. MD 5,; Tew, William P. MD 6; Klepin, Heidi D. MD, MS 7,; Wildes, Tanya M. MD, MS 8,; Dotan, Efrat MD 9,; Freedman, Rachel A. MD, MPH 10,; O'Connor, Tracey MD 11; Chow, Selina MD 12; Fenton, Mary Ann MD 13,; Moy, Beverly MD, MPH 14,; Chapman, Andrew E. DO 15,; Dale, William MD, PhD 1,3; Katheria, Vani BS 1,3; Kuderer, Nicole M. MD 16,; Lyman, Gary H. MD, MPH 17,; Magnuson, Allison DO 18; Muss, Hyman B. MD 19
doi : 10.1200/JCO.22.01440
Older women with high-risk early breast cancer (EBC) benefit from adjuvant chemotherapy, but their treatment is frequently complicated by toxic side effects, resulting in dose reductions and delays.
Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.
Fornecker, Luc-Matthieu MD, PhD 1,; Lazarovici, Julien MD 2; Aurer, Igor MD, PhD 3; Casasnovas, Rene-Olivier MD 4; Gac, Anne-Claire MD 5; Bonnet, Christophe MD 6; Bouabdallah, Krimo MD 7,; Feugier, Pierre MD 8; Specht, Lena MD 9; Molina, Lysiane MD 10; Touati, Mohamed MD 11; Borel, Cecile MD 12; Stamatoullas, Aspasia MD 13; Nicolas-Virelizier, Emmanuelle MD 14; Pascal, Laurent MD 15; Lugtenburg, Pieternella MD, PhD 16; Di Renzo, Nicola MD 17; Vander Borght, Thierry MD, PhD 18; Traverse-Glehen, Alexandra MD 19; Dartigues, Peggy MD 2; Hutchings, Martin MD 20; Versari, Annibale MD 21; Meignan, Michel MD 22; Federico, Massimo MD 23; Andre, Marc MD 18; for the LYSA-FIL-EORTC Intergroup
doi : 10.1200/JCO.21.01281
The prognosis of patients with early-stage unfavorable Hodgkin lymphoma remains unsatisfactory. We assessed the efficacy and safety of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (BV-AVD) in previously untreated, early-stage unfavorable Hodgkin lymphoma (ClinicalTrials.gov identifier: NCT02292979).
Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials.
Rutherford, Sarah C. MD 1,,; Yin, Jun PhD 2,; Pederson, Levi MS 2; Perez Burbano, Gabriela MS 2; LaPlant, Betsy MS 2; Shadman, Mazyar MD 3,; Li, Hongli MS 3; LeBlanc, Michael L. PhD 3,; Kenkre, Vaishalee P. MD 4,; Hong, Fangxin PhD 5,; Blum, Kristie A. MD 6,; Dockter, Travis MS 2; Martin, Peter MD 1,; Jung, Sin-Ho PhD 7,; Grant, Barbara MD 8; Rosenbaum, Cara MD 1,; Ujjani, Chaitra MD 3,; Barr, Paul M. MD 9,; Unger, Joseph M. PhD 3; Cheson, Bruce D. MD 10,; Bartlett, Nancy L. MD 11,; Kahl, Brad MD 11,; Friedberg, Jonathan W. MD 9,; Mandrekar, Sumithra J. PhD 2,; Leonard, John P. PhD 1,
doi : 10.1200/JCO.21.02301
Bone marrow biopsies (BMB) are performed before/after therapy to confirm complete response (CR) in patients with lymphoma on clinical trials. We sought to establish whether BMB add value in assessing response or predict progression-free survival (PFS) or overall survival (OS) outcomes in follicular lymphoma (FL) subjects in a large, multicenter, multitrial cohort.
Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III Trial.
Zhang, Haiyan MD, PhD 1; Fan, Zhiping MD 1; Huang, Fen MD 1; Han, Lijie MD, PhD 2; Xu, Yajing MD 3; Xu, Na MD, PhD 1; Deng, Lan MD, PhD 4; Wang, Shunqing MD, PhD 5; Lin, Dongjun MD, PhD 6; Luo, Xiaodan MD, PhD 7; Zhang, Qing MD, PhD 8; Liu, Xiaodan MD 9; Li, Xudong MD 10; Liang, Xinquan MD 11; Xie, Shuangfeng MD, PhD 12; Qu, Hong MD, PhD 13; Yu, Sijian MD, PhD 1; Zhou, Hongsheng MD, PhD 1; Shi, Pengcheng MD, PhD 1; Xuan, Li MD, PhD 1; Lin, Ren MD, PhD 1; Liu, Hui MD, PhD 1; Jin, Hua MD, PhD 1; Sun, Jing MD 1; Liu, Qifa MD 1,
doi : 10.1200/JCO.22.00767
It remains controversial whether busulfan-based versus total body irradiation (TBI)-based regimens have comparable outcomes in patients with acute lymphoblastic leukemia (ALL) undergoing allogeneic hematopoietic stem-cell transplantation (allo-HSCT).
Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia.
Schultz, Liora M. MD 1,,; Eaton, Anne PhD 2; Baggott, Christina PhD 3; Rossoff, Jenna MD 4,; Prabhu, Snehit PhD 3; Keating, Amy K. MD 5; Krupski, Christa DO, MPH 6,7,; Pacenta, Holly MD 8,9; Philips, Christine L. MD 6,7,; Talano, Julie-An MD 10,; Moskop, Amy MD 10; Baumeister, Susanne H.C. MD 11,; Myers, Gary Douglas MD 12,; Karras, Nicole A. MD 13; Brown, Patrick A. MD 14,; Qayed, Muna MD, MSc 15,; Hermiston, Michelle MD, PhD 16,; Satwani, Prakash MD 17,; Wilcox, Rachel BS 12,; Rabik, Cara A. MD, PhD 18; Fabrizio, Vanessa A. MD 5,19,20,; Chinnabhandar, Vasant MD 2; Kunicki, Michael BS 3; Mavroukakis, Sharon MS 3; Egeler, Emily PhD 3; Li, Yimei PhD 21,22,23; Mackall, Crystal L. MD 3,24,25,; Curran, Kevin J. MD 19,20,; Verneris, Michael R. MD 5,; Laetsch, Theodore W. MD 8,21,22,23,; Stefanski, Heather MD, PhD 2,
doi : 10.1200/JCO.22.01076
ponse and relapse after CD19-chimeric antigen receptor (CAR) T-cell therapy continue to challenge survival outcomes. Phase II landmark data from the ELIANA trial demonstrated nonresponse and relapse rates of 14.5% and 28%, respectively, whereas use in the real-world setting showed nonresponse and relapse rates of 15% and 37%.
A Population-Based Study of the Long-Term Risk of Infections Associated With Hospitalization in Childhood Cancer Survivors.
Chehab, Leena MD, MS 1; Doody, David R. MS 2; Esbenshade, Adam J. MD, MSCI 3,; Guilcher, Gregory M.T. MD 4,; Dvorak, Christopher C. MD 5,; Fisher, Brian T. DO, MSCE, MPH 6,7,; Mueller, Beth A. MPH, DPH 2,8,; Chow, Eric J. MD, MPH 2,; Rossoff, Jenna MD 9,10,,
doi : 10.1200/JCO.22.00230
se a significant risk during therapy for childhood cancer. However, little is known about the risk of infection in long-term survivors of childhood cancer.
Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide-Based Vaccine in Patients With Refractory Advanced Non-Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study.
Adotevi, Olivier MD, PhD 1,2,,; Vernerey, Dewi PhD 2,3,; Jacoulet, Pascale MD 4; Meurisse, Aurelia MSc 3; Laheurte, Caroline PhD 2,5; Almotlak, Hamadi MD 1; Jacquin, Marion MSc 6; Kaulek, Vincent PhD 4,; Boullerot, Laura MSc 2,5,6; Malfroy, Marine MSc 2; Orillard, Emeline MD 1,4; Eberst, Guillaume MD 2,4,; Lagrange, Aurelie MD 7; Favier, Laure MD 7; Gainet-Brun, Marie MD 4; Doucet, Ludovic MD 8,; Teixeira, Luis MD, PhD 8,; Ghrieb, Zineb PharmD 9; Clairet, Anne-Laure PharmD 10; Guillaume, Yves PharmD, PhD 10; Kroemer, Marie PharmD, PhD 10; Hocquet, Didier MD, PhD 11; Moltenis, Melanie PharmD 12; Limat, Samuel PharmD, PhD 2,10,; Quoix, Elisabeth MD, PhD 13,; Mascaux, Celine PharmD, PhD 14,; Debieuvre, Didier MD 15,; Fagnoni-Legat, Christine PharmD 10,; Borg, Christophe MD, PhD 1,2,6,; Westeel, Virginie MD, PhD 2,4,
doi : 10.1200/JCO.22.00096
Universal cancer peptide-based vaccine (UCPVax) is a therapeutic vaccine composed of two highly selected helper peptides to induce CD4+ T helper-1 response directed against telomerase.
Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial.
Drilon, Alexander MD 1,,; Subbiah, Vivek MD 2,; Gautschi, Oliver MD 3,; Tomasini, Pascale MD, MSc 4,; de Braud, Filippo MD 5,; Solomon, Benjamin J. MBBS, PhD 6,; Shao-Weng Tan, Daniel MBBS, PhD 7,; Alonso, Guzman MD 8; Wolf, Jurgen MD 9,; Park, Keunchil MD, PhD 10,; Goto, Koichi MD 11,; Soldatenkova, Victoria MSc 12,; Szymczak, Sylwia PhD 13,; Barker, Scott S. PhD 12,; Puri, Tarun MD 12,; Bence Lin, Aimee PhD 12,; Loong, Herbert MBBS 14,; Besse, Benjamin MD, PhD 15,
doi : 10.1200/JCO.22.00393
Selpercatinib, a first-in-class, highly selective, and potent CNS-active RET kinase inhibitor, is currently approved for the treatment of patients with RET fusion-positive non-small-cell lung cancer (NSCLC).
Emerging Therapies for the Management of Richter Transformation.
Smyth, Elizabeth MB BCh BAO, MRCPI, FRCPath 1,; Eyre, Toby A. MD, MBChB, DipMedEd, MRCP, FRCPath 2,; Cheah, Chan Y. MBBS(Hons), DMSc 1,3,,
doi : 10.1200/JCO.22.01028
AB Richter transformation (RT) refers to the development of an aggressive lymphoma in patients with underlying chronic lymphocytic leukemia/small lymphocytic lymphoma. Aside from a small subgroup of patients with clonally unrelated and previously untreated chronic lymphocytic leukemia, the disease responds poorly to standard therapies and prognosis is dismal.
Selective Targeting of RET Fusions in Lung Cancer.
Lin, Jessica J. MD 1,; Gainor, Justin F. MD 1,,
doi : 10.1200/JCO.22.01644
Being on the Other Side: An Oncologist's Perspective on Grieving.
MacDonald, Shannon MD 1,
doi : 10.1200/JCO.22.01363
Total Neoadjuvant Therapy for All Rectal Cancers: Is This the Way Ahead of the OPRA Trial?.
Kazi, Mufaddal MS, MCh; Saklani, Avanish MS, FRCS
doi : 10.1200/JCO.22.01166
Interpretation of the OPRA Study: Are Our Criteria Reliable Enough to Recommend Watch and Wait?.
Sutcuoglu, Osman MD; Rustamova Cennet, Nigar MD; Ozet, Ahmet MD; Ozdemir, Nuriye MD; Yaz[latin dotless i]c[latin dotless i], Ozan MD
doi : 10.1200/JCO.22.01260
Radio- or Chemotherapy Dose Escalation for Organ Preservation in Rectal Cancer?.
Socha, Joanna MD, PhD; Zolciak-Siwinska, Agnieszka MD, PhD; Bujko, Krzysztof MD, PhD
doi : 10.1200/JCO.22.01296
Reply to M. Kazi et al, O. Sutcuoglu et al, and J. Socha et al.
Aref, Amr MD; Abdalla, Ahmed MD
doi : 10.1200/JCO.22.01435
Clarifying the Equivocal Diagnosis of Cervical Intraepithelial Neoplasia 2: Still a Work in Progress.
Castle, Philip E. PhD, MPH; Wentzensen, Nicolas MD, PhD
doi : 10.1200/JCO.22.01268
Reply to P. Castle et al.
Berkhof, Johannes PhD; Dick, Stefanie MD; Kremer, Wieke MD, PhD; Bleeker, Maaike MD, PhD; Meijer, Chris MD, PhD
doi : 10.1200/JCO.22.01636
